		Krist	Charytan	Flamm	Fendrick	Lewis	Maisel	Pressman	S.Schwartz	Slaughter	Lacey	Bergthold	Edwards	Textor	Voting Member Average	Overall Average
1	For the treatment of parties with ARAS, how confident are you that the evidence is adequate to draw conclusions about safety and clinical effectiveness of the following renal artery interventions: *5 Highly Confident -4- 3 Uncertain -2- 1 Not Confident* **RAR**															
	Surgical renal artery reconstruction (RAR)?	2	3	3	3	1	2	4	4	4	4	2	3	3	**2.89**	**2.92**
	PTRA without stent placement?	2	2	4	3	3	3	2	3	3	3	2	5	3	**2.92**	**2.92**
	PTRAS with bare metal stents?	2	2	3	4	3	2	3	2	3	4	3	3	3	**2.85**	**2.85**
	PTRAS with drug-eluting stents?	1	1	1	1	1	1	1	1	1	1	1	1	1	**1.00**	**1.00**
2	Based on the evidence presented, how confident are you that the published results apply to: *5 Highly Confident -4- 3 Uncertain -2- 1 Not Confident*															
	Medicare patients with typical comorbidities?	3	3	3	4	5	5	4	4	3	4	4	3	3	**3.69**	**3.69**
	Providers (facilities/physicians) in community practice?	2	2	2	2	2	3	3	3	2	2	1	2	2	**2.15**	**2.15**
	Patient subgroups not represented in the study populations?	2	1	2	2	2	2	1	1	2	3	1	2	1	**1.67**	**1.69**
3	Based on the evidence presented for patients with ARAS, how confident are you that compared to aggressive medical treatment alone there are improved key health outcomes attributable to the following co-interventions: *5 Highly Confident -4- 3 Uncertain -2- 1 Not Confident*															
	Surgical RAR?	1	3	2	2	2	2	3	2	3	2	2	3	3	**2.31**	**2.31**
	PTRA without stent placement?	2	1	1	2	3	2	2	3	2	3	2	2	2	**2.08**	**2.08**
	PTRAS with bare metal stents?	2	3	3	3	3	3	3	3	3	4	3	4	4	**3.15**	**3.15**
	PTRAS with drug-eluting stents?**Evidence not adequate**														**NA**	**NA**
4	Based on the evidence presented, should Medicare national coverage of any non-medical treatments for astherosclerotic RAS be limited only to patients enrolled in qualified clinical research studies *5 Strongly disagree -4- 3 Uncertain -2- 1 Strongly Agree*	1	5	1	1	1	3	2	2	4	5	1	2	1	**2.36**	**2.23**

1